X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results And Provides Corporate Updates menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immunodeficiency disorder. Potential sales forecasted at $54.6M in 2024, rising to $450.9M by 2027.
By Chris Wack X4 Pharmaceuticals said that the Food and Drug Administration approved Xolremdi capsules for use in patients 12 years of age and older with WHIM syndrome to increase the number.